146 related articles for article (PubMed ID: 22933182)
21. E2F1-dependent oncogenic addiction of melanoma cells to MDM2.
Verhaegen M; Checinska A; Riblett MB; Wang S; Soengas MS
Oncogene; 2012 Feb; 31(7):828-41. PubMed ID: 21743494
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects.
Han Y; Ren Z; Wu Y; Chen Y; Cui Z; Zhu T; Ma M; Du Y; Dong S
Biochem Biophys Res Commun; 2020 Dec; 533(4):1069-1075. PubMed ID: 33012506
[TBL] [Abstract][Full Text] [Related]
23. Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis.
Xu Y; Diao Y; Qi S; Pan X; Wang Q; Xin Y; Cao X; Ruan J; Zhao Z; Luo L; Liu C; Yin Z
Cell Signal; 2013 May; 25(5):1176-85. PubMed ID: 23357534
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
25. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
26. MDM2 Antagonists Counteract Drug-Induced DNA Damage.
Vilgelm AE; Cobb P; Malikayil K; Flaherty D; Andrew Johnson C; Raman D; Saleh N; Higgins B; Vara BA; Johnston JN; Johnson DB; Kelley MC; Chen SC; Ayers GD; Richmond A
EBioMedicine; 2017 Oct; 24():43-55. PubMed ID: 29030058
[TBL] [Abstract][Full Text] [Related]
27. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
28. LYG-202 inhibits the proliferation of human colorectal carcinoma HCT-116 cells through induction of G1/S cell cycle arrest and apoptosis via p53 and p21(WAF1/Cip1) expression.
Liu W; Dai Q; Lu N; Wei L; Ha J; Rong J; Mu R; You Q; Li Z; Guo Q
Biochem Cell Biol; 2011 Jun; 89(3):287-98. PubMed ID: 21491996
[TBL] [Abstract][Full Text] [Related]
29. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
30. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Xu X; Liu Q; Zhang C; Ren S; Xu L; Zhao Z; Dou H; Li P; Zhang X; Gong Y; Shao C
Cell Death Dis; 2019 Mar; 10(4):282. PubMed ID: 30910997
[TBL] [Abstract][Full Text] [Related]
32. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
[TBL] [Abstract][Full Text] [Related]
33. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
34. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.
Moussa RS; Kovacevic Z; Richardson DR
Oncotarget; 2015 Oct; 6(30):29694-711. PubMed ID: 26335183
[TBL] [Abstract][Full Text] [Related]
35. Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype.
Wiley CD; Schaum N; Alimirah F; Lopez-Dominguez JA; Orjalo AV; Scott G; Desprez PY; Benz C; Davalos AR; Campisi J
Sci Rep; 2018 Feb; 8(1):2410. PubMed ID: 29402901
[TBL] [Abstract][Full Text] [Related]
36. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.
Gopal YN; Chanchorn E; Van Dyke MW
Mol Cancer Ther; 2009 Mar; 8(3):552-62. PubMed ID: 19276167
[TBL] [Abstract][Full Text] [Related]
37. Hinokiflavone, as a MDM2 inhibitor, activates p53 signaling pathway to induce apoptosis in human colon cancer HCT116 cells.
Zhang S; Wang Y; Sun Y; Zhao G; Wang J; Liu L; Liu F; Wang P; Yang J; Xu X
Biochem Biophys Res Commun; 2022 Feb; 594():93-100. PubMed ID: 35078113
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.
Wiech M; Olszewski MB; Tracz-Gaszewska Z; Wawrzynow B; Zylicz M; Zylicz A
PLoS One; 2012; 7(12):e51426. PubMed ID: 23251530
[TBL] [Abstract][Full Text] [Related]
39. Toxico-pharmacological evaluations of the small-molecule LQFM166: Inducer of apoptosis and MDM2 antagonist.
Dos Santos TRM; Garcia da Silva AC; de Carvalho FS; Sanz G; Vaz BG; Lião LM; Menegatti R; Valadares MC
Chem Biol Interact; 2018 Sep; 293():20-27. PubMed ID: 30057354
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
